For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- E2B/M2 Trial Results Announced
July 15, 2002
- Bayer BP to Start Hemophilia Awards Program
July 15, 2002
- MCC Acquires IC-Vec of UK Engaged in Gene Therapy
July 15, 2002
- Diabetic Nephropathy Approved as New Indication of Irbesartan
July 15, 2002
- Nippon Kayaku to Invest in Reverse Proteomics Research Institute
July 15, 2002
- Losartan Reduces Risk of Cardiovascular Death, Disease
July 15, 2002
- BUSINESS NEWS IN BRIEF
July 15, 2002
- Bayer BP Reports Possibility of Removal of Pathogenic Human Prion Protein
July 15, 2002
- AstraZeneca Decides to Provide Iressa before Listing
July 15, 2002
- RELOCATION
July 15, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 15, 2002
- Esmolol, Ferucarbotran Recommended for Approval
July 15, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 15, 2002
- WEBSITE NEWS
July 15, 2002
- Generics of 162 Active Ingredients Included in NHI Price List
July 15, 2002
- VITAL-NET Acquires Ohmori Yakuhin Tohoku
July 8, 2002
- Terumo's New Liposome Containing Anticancer Agent Effective
July 8, 2002
- Listed Drug Manufacturers' Combined Sales Up 4.9% to \6,043.6 Bil.
July 8, 2002
- Dr Ueda Calls For Increase in CRC and Enhanced Functions of IRB
July 8, 2002
- Otsuka: Consolidated Sales Up 2% to \489.9 Bil.
July 8, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…